#1 Clinical Trials Search in Europe

Milrinone

Milrinone is a medication being studied in various clinical trials for its potential benefits in treating cardiac and pulmonary conditions. These trials are exploring how milrinone may help improve heart function, reduce pulmonary hypertension, and manage symptoms in patients with heart failure, septic shock, and other related disorders. Researchers are investigating different administration methods and comparing milrinone to other treatments to determine its efficacy and safety profile.

Table of Contents

What is Milrinone?

Milrinone is a medication used to treat various heart and lung conditions. It’s also known by the brand name Primacor[1]. Milrinone belongs to a class of drugs called phosphodiesterase inhibitors, which help improve heart function and blood flow[2].

How Milrinone Works

Milrinone works in several ways to improve heart and lung function:

  • Improves heart contraction: It helps the heart muscle contract more strongly, which is called an inotropic effect[1].
  • Relaxes blood vessels: Milrinone causes blood vessels to widen, reducing the workload on the heart. This is known as vasodilation[1].
  • Enhances heart relaxation: It improves the heart’s ability to relax between beats, which is called a lusitropic effect[3].

Conditions Treated with Milrinone

Milrinone is used to treat several heart and lung conditions, including:

  • Heart failure: This is when the heart can’t pump blood effectively to meet the body’s needs[4].
  • Pulmonary hypertension: A condition where blood pressure in the lungs is too high[5].
  • Septic shock: A severe condition caused by infection that can lead to organ failure[1].
  • Persistent pulmonary hypertension of the newborn (PPHN): A condition in newborns where the blood flow to the lungs remains restricted after birth[6].

How Milrinone is Administered

Milrinone can be given in several ways:

  • Intravenous (IV) infusion: This is the most common method, where the drug is given directly into a vein[1].
  • Inhaled: Some studies are looking at giving milrinone through inhalation, which may have fewer side effects[5].
  • Oral tablets: Researchers are exploring slow-release oral forms of milrinone for long-term use[4].

Effectiveness of Milrinone

Milrinone has shown effectiveness in several areas:

  • Improving heart function: It can increase the amount of blood the heart pumps out with each beat[1].
  • Reducing pulmonary pressure: It can help lower high blood pressure in the lungs[5].
  • Helping newborns with PPHN: It may improve oxygen levels in babies with this condition[6].

Potential Side Effects

While milrinone can be effective, it may also cause side effects:

  • Low blood pressure: This is one of the most common side effects and may require additional treatment[5].
  • Irregular heartbeats: Milrinone can sometimes cause abnormal heart rhythms[1].
  • Bleeding: In rare cases, it may increase the risk of bleeding, especially in newborns[2].

Ongoing Research

Researchers are continuously studying milrinone to find new ways to use it and improve its effectiveness:

  • Comparing inhaled vs. intravenous use: Studies are looking at whether inhaled milrinone might be as effective as IV milrinone with fewer side effects[5].
  • Slow-release oral forms: Researchers are developing oral versions of milrinone that could be used for longer-term treatment of heart failure[4].
  • Use in specific surgeries: Studies are examining how milrinone might help patients undergoing heart valve surgeries[7].
Aspect Details
Primary Conditions Studied Septic shock, persistent pulmonary hypertension in newborns, heart failure, pulmonary hypertension in cardiac surgery patients
Administration Methods Intravenous infusion, inhaled, slow-release oral formulation
Key Outcomes Measured Cardiac output, pulmonary artery pressure, oxygenation, mortality rates, length of hospital stay
Comparisons Placebo, sildenafil, dobutamine
Safety Monitoring Systemic hypotension, arrhythmias, bleeding
Patient Populations Adults with heart conditions, newborns with pulmonary hypertension, cardiac surgery patients
Potential Benefits Improved heart function, reduced pulmonary pressure, better oxygenation

FAQ

  • What is milrinone used for in clinical trials? Milrinone is being studied for various conditions including septic shock, persistent pulmonary hypertension in newborns, heart failure, and pulmonary hypertension in cardiac surgery patients. It's being investigated for its ability to improve heart function and reduce pulmonary pressure.
  • How is milrinone administered in these trials? Milrinone is administered in different ways depending on the trial. Some studies use intravenous infusion, while others are exploring inhaled milrinone or even slow-release oral formulations. The method of administration can affect how the drug works in the body.
  • What are some potential benefits of milrinone being studied? Potential benefits being studied include improved cardiac output, reduced pulmonary artery pressure, better oxygenation, and overall improved heart function. Some trials are also looking at its effects on mortality rates and length of hospital stay.
  • Are there any side effects of milrinone being monitored in these trials? Yes, researchers are monitoring for side effects such as systemic hypotension (low blood pressure), arrhythmias (irregular heartbeats), and bleeding. The trials are designed to assess both the efficacy and safety profile of milrinone.
  • How does milrinone compare to other treatments in these studies? Some trials are comparing milrinone to placebo, while others are comparing it to other medications like sildenafil or dobutamine. These comparisons help researchers understand the relative benefits and risks of milrinone compared to existing treatments.

Ongoing Clinical Trials on Milrinone

  • Study on Milrinone for Preventing Delayed Brain Ischemia in Patients with Severe Subarachnoid Hemorrhage

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Esmolol Hydrochloride, Dobutamine, and Milrinone for Patients with Cardiogenic Shock on V-A ECMO Support

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Milrinone Infusion for Treating Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Pulmonary Hypertension: A condition characterized by high blood pressure in the arteries of the lungs, which can lead to heart failure.
  • Cardiac Output: The amount of blood the heart pumps through the circulatory system in a minute.
  • Septic Shock: A severe condition that occurs when an infection leads to dangerously low blood pressure and organ failure.
  • Inotrope: A type of medication that changes the force of heart muscle contractions.
  • Phosphodiesterase Inhibitor: A class of drugs that work by blocking the enzyme phosphodiesterase, which can help improve heart function and reduce pulmonary pressure.
  • Echocardiogram: An ultrasound test that uses sound waves to create images of the heart, allowing doctors to see its size, shape, and function.
  • Cardiopulmonary Bypass (CPB): A technique that temporarily takes over the function of the heart and lungs during surgery.
  • Oxygenation Index: A measure of the oxygen levels in the blood, used to assess the severity of respiratory failure.
  • Ventricular Strain: A measure of how much the heart muscle deforms during contraction, used to assess heart function.
  • Persistent Pulmonary Hypertension of the Newborn (PPHN): A serious condition in newborns where the blood pressure in the lungs remains high after birth, making it difficult for the baby to breathe.

References

  1. https://clinicaltrials.gov/study/NCT05122884
  2. https://clinicaltrials.gov/study/NCT04391478
  3. https://clinicaltrials.gov/study/NCT01841177
  4. https://clinicaltrials.gov/study/NCT01956006
  5. https://clinicaltrials.gov/study/NCT05838846
  6. https://clinicaltrials.gov/study/NCT01088997
  7. https://clinicaltrials.gov/study/NCT06077721